Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management


Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management Banner

Add to Calendar Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management 12/10/2021 7:00:00 AM 12/10/2021 9:30:00 AM America/New_York false MM/DD/YYYY


Date & Location
Friday, December 10, 2021, 7:00 AM - 9:30 AM, Atlanta, GA

Overview
A CME-certified Friday Satellite Symposium preceding the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

B-cell non-Hodgkin lymphoma (NHL) management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy, the majority of which are due to adverse events (AEs), and data suggest that the management of AEs is not consistent with recommendations. Moreover, despite advances in treatment, many patients will relapse, and subsequent treatment decisions are challenging. Real-world and prospective data regarding the impact of treatment sequence on patient outcomes are just emerging, and there is no guidance on sequencing therapies for patients who discontinue first-line therapy due to toxicity or progression.

To help hematologist-oncologists keep pace with recommended AE management strategies and emerging data for treatment sequencing, this CME-certified ASH Friday Satellite Symposium will consist of evidence-based presentations interspersed with real-world patient cases designed to provide learners with expert faculty insights and analysis of the clinical implications of new and emerging data for minimizing treatment-emergent AEs and managing treatment sequencing decisions in patients with CLL/SLL.

For complete activity information including registration, please click here.


Objectives
Upon completion of this activity, participants should be better able to:

  1. Identify the safety profiles of the novel targeted agents used to treat CLL/SLL
  2. Outline treatment adjustments based on current and emerging data to effectively mitigate AEs while still achieving the deepest and most durable response
  3. Evaluate recent data on novel treatment sequencing strategies for managing R/R CLL/SLL and their potential implications for clinical practice

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences, Lymphoma Research Foundation and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Advanced Practice Nurses, Nurses, Physician Assistants: Advanced practice nurses, nurses and physician assistants may participate in this educational activity and earn a letter of attendance as AANP, ANCC and AAPA accept AMA PRA Category 1 Credits™ through their reciprocity agreements.


Credits
AMA PRA Category 1 Credits™ (2.00 hours), Non-Physician Attendance (2.00 hours)